NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.40+0.17 (+2.73%)
Close on Nov 13, 2026Market cap $29.30MP/E –Yield 0.00%
NextCure EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
NextCure's EPS for the twelve months ending Jun 30, 2026 was -$10.26. For fiscal 2025 it was -$19.65. The highest annual figure on record is -$15.96 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.65 | – |
| FY2024 | Dec 31, 2024 | -$23.88 | – |
| FY2023 | Dec 31, 2023 | -$27.00 | – |
| FY2022 | Dec 31, 2022 | -$32.28 | – |
| FY2021 | Dec 31, 2021 | -$30.12 | – |
| FY2020 | Dec 31, 2020 | -$15.96 | – |
| FY2019 | Dec 31, 2019 | -$25.80 | – |
| FY2018 | Dec 31, 2018 | -$199.68 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.80 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.87 | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.37 | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.22 | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.29 | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.70 | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.97 | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.95 | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.61 | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.32 | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.22 | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.12 | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.96 | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.47 | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.16 | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.80 | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.88 | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.35 | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.80 | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.80 | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.20 | -281.8% |
| Q4 FY2020 | Dec 31, 2020 | -$6.73 | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.08 | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.36 | – |
| Q1 FY2020 | Mar 31, 2020 | $3.96 | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.44 | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.32 | – |
| Q1 FY2019 | Mar 31, 2019 | -$53.52 | – |
| Q4 FY2018 | Dec 31, 2018 | -$60.03 | – |
| Q3 FY2018 | Sep 30, 2018 | -$50.04 | – |
| Q2 FY2018 | Jun 30, 2018 | -$45.84 | – |
| Q1 FY2018 | Mar 31, 2018 | -$43.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?